問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2024-02-21

李淑媛
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

10Cases

2025-09-01 - 2029-12-31

Not yet recruiting
A Phase 2, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540A in Healthy Females 16 to 26 Years of Age
  • Condition/Disease

    Healthy

  • Test Drug

    Injectables

Participate Sites
6Sites

Recruiting6Sites

2022-12-15 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting5Sites

Recruiting4Sites

2025-12-01 - 2029-01-04

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

2025-01-01 - 2031-01-26

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-01-01 - 2031-01-26

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-01-01 - 2031-01-26

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-11-15 - 2033-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2024-01-01 - 2025-09-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting5Sites

Terminated2Sites

2024-01-01 - 2025-09-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-04-19 - 2024-03-21

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites